1-4 of 4
Dawn Wilson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Philipp Kiewe, Ulrich Germing, MD, Katharina S. Götze, MD, Karin Mayer, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Joerg Chromik, Dawn Wilson, Xiaosha Zhang, PhD, Chris Rovaldi, MSc, Abderrahmane Laadem, MD, Matthew Leigh Sherman, MD, Kenneth Morris Attie, MD, Joseph Reynolds, PhD, Peter Guest Linde, MD, Aristoteles Giagounidis, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2982.
https://doi.org/10.1182/blood.V130.Suppl_1.2982.2982
Published: 2017
Journal Articles

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Aristoteles Giagounidis, MD PhD, Uwe Platzbecker, MD, Ulrich Germing, MD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD
Journal: Blood
Blood (2015) 126 (23): 92.
https://doi.org/10.1182/blood.V126.23.92.92
Published: 2015
Journal Articles

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Antonio Piga, MD, Silverio Perrotta, MD, M.Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, Aldo Filosa, MD, Antonello Pietrangelo, MD, Vincenzo Caruso, MD, Gian Luca Forni, MD, Xiaosha Zhang, Ashley Bellevue, Dawn Wilson, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD
Journal: Blood
Blood (2015) 126 (23): 752.
https://doi.org/10.1182/blood.V126.23.752.752
Published: 2015
Journal Articles

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD
Journal: Blood
Blood (2015) 126 (23): 2862.
https://doi.org/10.1182/blood.V126.23.2862.2862
Published: 2015